Puratrophin 1 CRISPR/Cas9 KO Plasmid (h): sc-411825
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Puratrophin 1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Puratrophin 1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Puratrophin 1 CRISPR/Cas9 KO Plasmid (h) | sc-411825 | 20 µg | $397.00 |
Overview
PLEKHG4 encodes Puratrophin 1, a multidomain protein implicated in neuronal and cytoskeletal regulation through Rho family GTPase signaling. As a putative Rho guanine nucleotide exchange factor–related protein, it is linked to modulation of actin dynamics, membrane trafficking, and neurite architecture, processes central to synaptic maintenance and intracellular transport. PLEKHG4 expression is enriched in the nervous system, supporting roles in neuronal development and circuitry stability. Genetic variation and altered function of Puratrophin 1 have been associated with neurodegenerative and movement-disorder phenotypes, including spinocerebellar ataxia, motivating mechanistic studies in relevant cell models.
Puratrophin 1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PLEKHG4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PLEKHG4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PLEKHG4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Puratrophin 1 protein expression.
This CRISPR knockout system enables efficient generation of PLEKHG4-deficient cell models for investigation of Puratrophin 1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PLEKHG4 exon(s) critical for Puratrophin 1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PLEKHG4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Puratrophin 1 CRISPR/Cas9 KO Plasmid (h) and Puratrophin 1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PLEKHG4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Puratrophin 1 HDR Plasmid (h) and Puratrophin 1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PLEKHG4 homology arms to support homology-directed repair at defined PLEKHG4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.